Financial Statements 191 4 Reserves Share Capital Other Profit and 2009 2008 premium account redemption reserve reserves loss account Total Total $m $m $m $m $m $m At beginning of year 2,046 94 2,743 18,098 22,981 22,582 Profit for the year 2,658 2,658 3,436 Dividends 3,026 3,026 2,767 Gain on cash flow hedge in anticipation of debt issue 1 1 1 Share-based payment 179 179 178 Share re-purchases 607 Share premium 134 134 158 At end of year 2,180 94 2,922 17,731 22,927 22,981 Distributable reserves at end of year 1,841 17,731 19,572 18,787 As permitted by section 408 4 of the Companies Act 2006, the Company has not presented its own profit and loss account.
At 31 December 2009, $17,731m 31 December 2008: $16,946m of the profit and loss account reserve was available for distribution.
Included in other reserves is a special reserve of $157m, arising on the redenomination of share capital in 1999.
During 2008, the Company adopted the requirements of UITF Abstract 44 Group and Treasury Share Transactions.
Included within other reserves at 31 December 2009 is $1,081m 31 December 2008: $902m in respect of cumulative share-based payment awards.
These amounts are not available for distribution.
5 Reconciliation of movement in shareholders funds 2009 2008 $m $m At beginning of year 23,343 22,946 Net profit for the financial year 2,658 3,436 Dividends 3,026 2,767 Gain on cash flow hedge in anticipation of debt issue 1 1 Share-based payment 179 178 Issue of AstraZeneca PLC Ordinary Shares 135 159 Re-purchase of AstraZeneca PLC Ordinary Shares 610 Net decrease increase in shareholders funds 53 397 Shareholders funds at end of year 23,290 23,343 Details of dividends paid and payable to shareholders are given in Note 21 to the Group Financial Statements on page 154.
6 Share capital Authorised Allotted, called-up and fully paid 2009 2009 2008 $m $m $m Issued Ordinary Shares $0.25 each 363 363 362 Unissued Ordinary Shares $0.25 each 237 Redeemable Preference Shares 1 each 50,000 600 363 362 The total authorised number of Ordinary Shares at 31 December 2009 was 2,400,000,000, of which 1,450,958,562 Ordinary Shares were in issue.
The Redeemable Preference Shares carry limited class voting rights and no dividend rights.
This class of shares is capable of redemption at par at the option of the Company on the giving of seven days written notice to the registered holder of the shares.
AstraZeneca Annual Report and Form 20-F Information 2009 AstraZeneca Annual Report and Form 20-F Information 2009
